LOBE:CC News and Press, Lobe Sciences Ltd. From 06/07/23

Phillips also named President of Altemia & Co., a Lobe Sciences Company Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxte...

Distribution Agreement Grants Pentec Exclusive Distribution Rights for Altemia Lobe’s Novel Sickle Cell Anemia Medical Food Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat...

2023-04-27 16:00:04 ET Lobe Sciences (CSE:LOBE,OTCQB:LOBEF) has significantly expanded its portfolio following its acquisition of Altemia & Company. The purchase also sets Lobe Sciences up for revenue generation in the short term, helping secure funds for orphan drug research and ...

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the " Company "), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an u...

VANCOUVER, BC / ACCESSWIRE / April 19, 2023 / The Power Play by The Market Herald has announced the release of new interviews with ARway, Silver Bullet Mines, Galantas Gold, Lobe Sciences, Northstar Gold and Rover Metals discussing their latest news. The Power Play by The Market Herald provides...

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023 Acquisition also Includes an Inte...

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) -  Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (" Lobe " or the " Company ") a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today an...

Dosing In Human Clinical Trial To Commence Within Weeks Vancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused med...

(NewsDirect) By Richard Dal Monte As early as the 1950s, scientists were researching the possible therapeutic benefits of psychedelics such as LSD and psilocybin mushrooms. But by the late 1960s, when the counterculture looked to psychedelics to turn on, tune in and drop out, those su...

Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe Sciences QCL agrees to supply Lobe Sciences research and commercial quantities of two new chemical entities, L-130 and L-131 under an exclusive arran...